In-hospital use of continuous glucose monitoring may offer improvements in glycemic control and reduced exposure to COVID-19 for healthcare professionals.
Experts provide recommendations for effective implementation of telehealth for diabetes care, with a focus on patient-to-clinic video encounters.
Changes to restrictions for telemedicine may have important implications for the management of adult and pediatric diabetes during the COVID-19 pandemic.
For patients with T2D, glycemic control is similar with use of regular human insulin and rapid-acting insulin when delivered with a wearable insulin delivery device, V-Go.
Real-world data support the benefit of using the Medtronic MiniMed 670G insulin pump system for glycemic control in type 1 diabetes.
Applying functional data analysis to continuous glucose monitoring data can assist in identifying differences in maternal glucose control during pregnancy, which might go unnoticed using standard metrics.
Use of continuous glucose monitoring devices positively correlated with fewer sleep disturbances in children with type 1 diabetes but higher sleep disturbances in their parents.
Companion Medical announced that it has received clearance from the Food and Drug Administration (FDA) for a new bolus calculator for fixed dosing and meal estimation to be used with the InPen system.
Access to a patient portal through both mobile and computer platforms was associated with significantly improved outcomes in diabetes management.
Medtronic is recalling certain MiniMed 600 Series insulin pumps due to a missing or broken retainer ring that can potentially lead to the under or over delivery of insulin.
A novel dual-hormone artificial pancreas system that delivers both rapid insulin and pramlintide was found to improve glucose control.